Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors-Reference-Cited by-同舟云学术

Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors

Published:2007-10 Issue:4 Volume:52 Page:1082-1089
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Cussenot Olivier,Azzouzi Abdel-Rahmène,Nicolaiew Nathalie,Mangin Philippe,Cormier Luc,Fournier Georges,Valeri Antoine,Cancel-Tassin Géraldine

Publisher

Elsevier BV

Subject

Urology

Reference35 articles.

1. Progress toward identifying aggressive prostate cancer;Eisenberger;N Engl J Med,2004

2. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II;Makridakis;Pharmacogenetics,2000

3. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis;Ntais;Cancer Epidemiol Biomarkers Prev,2003

4. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial;Andriole;J Urol,2004

5. Update on prostate cancer chemoprevention;Lowe;Pharmacotherapy,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testosterone Enanthate Induces Cell Death in Human Colon (HCT) and Gastric (AGS) Cancer Cells;Pakistan Journal of Zoology;2021

2. Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer;Oncology Letters;2020-09-18

3. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer;BMC Urology;2019-01-07

4. Hormone-Responsive Cancers;Yen and Jaffe's Reproductive Endocrinology;2019

5. Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors;Strahlentherapie und Onkologie;2017-07-10